EnviroTech :: Biotech
BPA: Brisbane Facility to Bridge Infrastructure Gap in Australia’s Biotechnology Manufacturing Chain
4:42 AM MDT | May 26, 2010 | Deepti Ramesh
BioPharmaceuticals Australia (BPA; Brisbane) tells CW that the total investment involved in constructing the previously announced mammalian biopharmaceutical manufacturing facility at Brisbane, Australia would be about A$61 million ($51 million). DSM Biologics, a DSM subsidiary, announced earlier this month that it had entered into a partnership with state and local authorities in Australia to build and operate the mammalian biopharmaceutical manufacturing facility at Brisbane. The Queensland and Australian governments will provide full financial funding for the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee